{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:59:36Z","timestamp":1794916776295,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Even if adoptive cell transfer (ACT) has already shown great clinical efficiency in different types of disease, such as cancer, some adverse events consistently occur, and suicide genes are an interesting system to manage these events. Our team developed a new medical drug candidate, a chimeric antigen receptor (CAR) targeting interleukin-1 receptor accessory protein (IL-1RAP), which needs to be evaluated in clinical trials with a clinically applicable suicide gene system. To prevent side effects and ensure the safety of our candidate, we devised two constructs carrying an inducible suicide gene, RapaCasp9-G or RapaCasp9-A, containing a single-nucleotide polymorphism (rs1052576) affecting the efficiency of endogenous caspase 9. These suicide genes are activated by rapamycin and based on the fusion of human caspase 9 with a modified human FK-binding protein, allowing conditional dimerization. RapaCasp9-G- and RapaCasp9-A-expressing gene-modified T cells (GMTCs) were produced from healthy donors (HDs) and acute myeloid leukemia (AML) donors. The RapaCasp9-G suicide gene demonstrated better efficiency, and we showed its in vitro functionality in different clinically relevant culture conditions. Moreover, as rapamycin is not pharmacologically inert, we also demonstrated its safe use as part of our therapy.<\/jats:p>","DOI":"10.1038\/s41434-023-00404-2","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T03:02:47Z","timestamp":1683860567000},"page":"706-713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells"],"prefix":"10.1038","volume":"30","author":[{"given":"Lucie","family":"Bouquet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"B\u00f4le-Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Warda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Neto Da Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rim","family":"Trad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Nicod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik","family":"Haderbache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Genin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0119-3919","authenticated-orcid":false,"given":"Christophe","family":"Ferrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0564-0926","authenticated-orcid":false,"given":"Marina","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"404_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/bs.ai.2015.12.006","volume":"130","author":"JC Yang","year":"2016","unstructured":"Yang JC, Rosenberg SA. Adoptive T-cell therapy for cancer. Adv Immunol. 2016;130:279\u201394.","journal-title":"Adv Immunol"},{"key":"404_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114:535\u201346.","journal-title":"Blood."},{"key":"404_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2567.2008.03015.x","volume":"126","author":"JD Stone","year":"2009","unstructured":"Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology. 2009;126:165\u201376.","journal-title":"Immunology."},{"key":"404_CR4","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1084\/jem.192.11.1637","volume":"192","author":"C Yee","year":"2000","unstructured":"Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000;192:1637\u201344.","journal-title":"J Exp Med."},{"key":"404_CR5","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250.","journal-title":"Front Immunol"},{"key":"404_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J."},{"key":"404_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"key":"404_CR8","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1038\/cti.2014.11","volume":"3","author":"SK Tey","year":"2014","unstructured":"Tey SK. Adoptive T-cell therapy: adverse events and safety switches. Clin Transl Immunol. 2014;3:e17.","journal-title":"Clin Transl Immunol"},{"key":"404_CR9","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1182\/blood.2021010784","volume":"137","author":"MC Foster","year":"2021","unstructured":"Foster MC, Savoldo B, Lau W, Rubinos C, Grover N, Armistead P, et al. Utility of a safety switch to abrogate CD19.CAR T-cell\u2013associated neurotoxicity. Blood. 2021;137:3306\u20139.","journal-title":"Blood."},{"key":"404_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/13543776.2016.1211640","volume":"26","author":"SA Navarro","year":"2016","unstructured":"Navarro SA, Carrillo E, Gri\u00f1\u00e1n-Lis\u00f3n C, Mart\u00edn A, Per\u00e1n M, Marchal JA, et al. Cancer suicide gene therapy: a patent review. Expert Opin Ther Pat. 2016;26:1095\u2013104.","journal-title":"Expert Opin Ther Pat"},{"key":"404_CR11","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.exphem.2016.07.011","volume":"44","author":"X Zhou","year":"2016","unstructured":"Zhou X, Brenner MK. Improving the safety of T-Cell therapies using an inducible caspase-9 gene. Exp Hematol. 2016;44:1013\u20139.","journal-title":"Exp Hematol"},{"key":"404_CR12","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.ymthe.2018.03.001","volume":"26","author":"M Stavrou","year":"2018","unstructured":"Stavrou M, Philip B, Traynor-White C, Davis CG, Onuoha S, Cordoba S, et al. A rapamycin-activated caspase 9-based suicide gene. Mol Therapy. 2018;26:1266\u201376.","journal-title":"Mol Therapy"},{"key":"404_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.mt.6300190","volume":"15","author":"C Bonini","year":"2007","unstructured":"Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F, et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Therapy. 2007;15:1248\u201352.","journal-title":"Mol Therapy"},{"key":"404_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.addr.2015.05.009","volume":"99","author":"Z Karjoo","year":"2016","unstructured":"Karjoo Z, Chen X, Hatefi A. Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev. 2016;99:113\u201328.","journal-title":"Adv Drug Deliv Rev."},{"key":"404_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood.V97.1.63","volume":"97","author":"P Tiberghien","year":"2001","unstructured":"Tiberghien P. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001;97:63\u201372.","journal-title":"Blood."},{"key":"404_CR16","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pul\u00e8 MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105:4247\u201354.","journal-title":"Blood."},{"key":"404_CR17","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673\u201383.","journal-title":"N Engl J Med"},{"key":"404_CR18","doi-asserted-by":"publisher","first-page":"e004222","DOI":"10.1136\/jitc-2021-004222","volume":"10","author":"R Trad","year":"2022","unstructured":"Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer. 2022;10:e004222.","journal-title":"J Immunother Cancer."},{"key":"404_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","volume":"79","author":"W Warda","year":"2019","unstructured":"Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, et al. CML hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor-engineered T cells. Cancer Res. 2019;79:663\u201375.","journal-title":"Cancer Res"},{"key":"404_CR20","first-page":"4997","volume":"37","author":"S Ozdogan","year":"2017","unstructured":"Ozdogan S, Kafadar A, Yilmaz SG, Timirci-Kahraman O, Gormus U, Isbir T. Role of caspase-9 gene Ex5+32 G>A (rs1052576) variant in susceptibility to primary brain tumors. Anticancer Res. 2017;37:4997\u20135000.","journal-title":"Anticancer Res"},{"key":"404_CR21","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.21873\/anticanres.13361","volume":"39","author":"S Ercan","year":"2019","unstructured":"Ercan S, Arinc S, Yilmaz SG, Altunok C, Yaman F, Isbir T. Investigation of caspase 9 gene polymorphism in patients with non-small cell lung cancer. Anticancer Res. 2019;39:2437\u201341.","journal-title":"Anticancer Res"},{"key":"404_CR22","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/carcin\/bgl196","volume":"28","author":"Q Lan","year":"2007","unstructured":"Lan Q, Zheng T, Chanock S, Zhang Y, Shen M, Wang SS, et al. Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis. 2007;28:823\u20137.","journal-title":"Carcinogenesis"},{"key":"404_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00439-009-0645-6","volume":"125","author":"AS Andrew","year":"2009","unstructured":"Andrew AS, Gui J, Sanderson AC, Mason RA, Morlock EV, Schned AR, et al. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet. 2009;125:527\u201339.","journal-title":"Hum Genet"},{"key":"404_CR24","first-page":"103385","volume":"71","author":"C Nicod","year":"2023","unstructured":"Nicod C, da Rocha MN, Warda W, Roussel X, Haderbache R, Seffar E, et al. CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. Curr Res Transl Med. 2023;71:103385.","journal-title":"Curr Res Transl Med."},{"key":"404_CR25","doi-asserted-by":"crossref","unstructured":"Da Rocha MN, Guiot M, Nicod C, Trad R, Bouquet L, Haderbache R, et al. Coated recombinant target protein helps explore IL-1RAP CAR T-cell functionality in vitro. Immunol Res. 2023;71:276\u201382.","DOI":"10.1007\/s12026-022-09348-y"},{"key":"404_CR26","doi-asserted-by":"publisher","first-page":"e0122888","DOI":"10.1371\/journal.pone.0122888","volume":"10","author":"A Nalbandian","year":"2015","unstructured":"Nalbandian A, Llewellyn KJ, Nguyen C, Yazdi PG, Kimonis VE. Rapamycin and chloroquine: the in vitro and in vivo effects of autophagy-modifying drugs show promising results in valosin containing protein multisystem proteinopathy. PLoS One. 2015;10:e0122888.","journal-title":"PLoS One."},{"key":"404_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351.","journal-title":"Mol Ther"},{"key":"404_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36:133\u201351.","journal-title":"J Immunother"},{"key":"404_CR29","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5:197ra103\u2013197ra103.","journal-title":"Sci Transl Med"},{"key":"404_CR30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122:863\u201371.","journal-title":"Blood."},{"key":"404_CR31","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncol. 2016;3:16011.","journal-title":"Mol Ther Oncol"},{"key":"404_CR32","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/ki.1996.417","volume":"50","author":"TF Andoh","year":"1996","unstructured":"Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int. 1996;50:1110\u20137.","journal-title":"Kidney Int"},{"key":"404_CR33","doi-asserted-by":"publisher","first-page":"23996","DOI":"10.18632\/oncotarget.15098","volume":"8","author":"P Li","year":"2017","unstructured":"Li P, Zhou L, Zhao T, Liu X, Zhang P, Liu Y, et al. Caspase-9: structure, mechanisms and clinical application. Oncotarget. 2017;8:23996\u20134008.","journal-title":"Oncotarget"},{"key":"404_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0092-8674(00)81477-4","volume":"94","author":"R Hakem","year":"1998","unstructured":"Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 1998;94:339\u201352.","journal-title":"Cell."},{"key":"404_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1517\/14728222.2014.961425","volume":"19","author":"B Kim","year":"2015","unstructured":"Kim B, Srivastava SK, Kim SH. Caspase-9 as a therapeutic target for treating cancer. Expert Opinion Therapeutic Targets. 2015;19:113\u201327.","journal-title":"Expert Opinion Therapeutic Targets"},{"key":"404_CR36","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118:1255\u201363.","journal-title":"Blood"},{"key":"404_CR37","doi-asserted-by":"crossref","unstructured":"Falcon C, Smith L, Al-Obaidi M, Abu Zaanona M, Purvis K, Minagawa K, et al. Combinatorial suicide gene strategies for the safety of cell therapies. Front Immunol. 2022;13. https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.975233.","DOI":"10.3389\/fimmu.2022.975233"}],"updated-by":[{"DOI":"10.1038\/s41434-024-00487-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000}}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-023-00404-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-023-00404-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-023-00404-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T02:03:19Z","timestamp":1734660199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-023-00404-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1038\/s41434-023-00404-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2246139\/v1","asserted-by":"object"}]},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There was an error in the supplementary material.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41434-024-00487-5","URL":"https:\/\/doi.org\/10.1038\/s41434-024-00487-5","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MD and CF are co-funders and share holders of CanCell Therapeutics, WW, MNDR, DG and CN are employes of CanCell Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Donors from the French Blood Establishment provided written informed consent, and the study was conducted in accordance with appropriate ethical guidelines (Declaration of Helsinki) and approved by the local ethics CPP-Est committee (France). AML samples were collected from patients with AML at follow-up or diagnosis included, after consent, in the approved AML samples collection, CAR-LAM, N\u00b0 CPP: CPP2019-03-022a.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}